Rituximab as front-line treatment in refractory autoimmune hemolytic anemia

Minerva Pediatr (Torino). 2022 Dec;74(6):801-802. doi: 10.23736/S2724-5276.19.05672-X. Epub 2019 Nov 11.

Authors

Dafni Moriki¹, Maria A Karalexi², Kassiani Kekkou¹, Michalis Kalogiannis¹, Vassiliki Papaevangelou¹, Ioannis Petrocheilos¹

Affiliations

¹ Third Department of Pediatrics, General University Hospital "Attikon, " National and Kapodistrian University of Athens, Athens, Greece.
² Third Department of Pediatrics, General University Hospital "Attikon, " National and Kapodistrian University of Athens, Athens, Greece - marykaralexi@windowslive.com.

PMID: 31729205
DOI: 10.23736/S2724-5276.19.05672-X

No abstract available

MeSH terms

Anemia, Hemolytic, Autoimmune* / drug therapy
Antibodies, Monoclonal, Murine-Derived
Humans
Rituximab / therapeutic use
Treatment Outcome

Substances

Rituximab
Antibodies, Monoclonal, Murine-Derived